99 related articles for article (PubMed ID: 38776868)
1. CAR T-Cell Immunotherapy in Minority Patients with Lymphoma.
Ghilardi G; Williamson S; Pajarillo R; Paruzzo L; Chen L; Grady C; Doucette A; Nemecek E; Gabrielli G; Barta SK; Svoboda J; Chong EA; Yelton R; Nasta SD; Landsburg DJ; Ugwuanyi O; Chen AI; Schachter L; White G; Ballard HJ; Weber E; Curley C; Porter DL; Garfall AL; Hwang WT; Guerra CE; Maziarz RT; Schuster SJ; Ruella M
NEJM Evid; 2024 Apr; 3(4):EVIDoa2300213. PubMed ID: 38776868
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of a novel anti-CD19 chimeric antigen receptor T cell product targeting a membrane-proximal domain of CD19 with fast on- and off-rates against non-Hodgkin lymphoma: a first-in-human study.
Zhang Y; Patel RP; Kim KH; Cho H; Jo JC; Jeong SH; Oh SY; Choi YS; Kim SH; Lee JH; Angelos M; Guruprasad P; Cohen I; Ugwuanyi O; Lee YG; Pajarillo R; Cho JH; Carturan A; Paruzzo L; Ghilardi G; Wang M; Kim S; Kim SM; Lee HJ; Park JH; Cui L; Lee TB; Hwang IS; Lee YH; Lee YJ; Porazzi P; Liu D; Lee Y; Kim JH; Lee JS; Yoon DH; Chung J; Ruella M
Mol Cancer; 2023 Dec; 22(1):200. PubMed ID: 38066564
[TBL] [Abstract][Full Text] [Related]
3. Impact of
Shouval R; Alarcon Tomas A; Fein JA; Flynn JR; Markovits E; Mayer S; Olaide Afuye A; Alperovich A; Anagnostou T; Besser MJ; Batlevi CL; Dahi PB; Devlin SM; Fingrut WB; Giralt SA; Lin RJ; Markel G; Salles G; Sauter CS; Scordo M; Shah GL; Shah N; Scherz-Shouval R; van den Brink M; Perales MA; Palomba ML
J Clin Oncol; 2022 Feb; 40(4):369-381. PubMed ID: 34860572
[TBL] [Abstract][Full Text] [Related]
4. CD19-targeted chimeric antigen receptor T-cell therapy for CNS relapsed or refractory acute lymphocytic leukaemia: a post-hoc analysis of pooled data from five clinical trials.
Leahy AB; Newman H; Li Y; Liu H; Myers R; DiNofia A; Dolan JG; Callahan C; Baniewicz D; Devine K; Wray L; Aplenc R; June CH; Grupp SA; Rheingold SR; Maude SL
Lancet Haematol; 2021 Oct; 8(10):e711-e722. PubMed ID: 34560014
[TBL] [Abstract][Full Text] [Related]
5. Phase I Trial of Fourth-Generation Anti-CD19 Chimeric Antigen Receptor T Cells Against Relapsed or Refractory B Cell Non-Hodgkin Lymphomas.
Zhou X; Tu S; Wang C; Huang R; Deng L; Song C; Yue C; He Y; Yang J; Liang Z; Wu A; Li M; Zhou W; Du J; Guo Z; Li Y; Jiao C; Liu Y; Chang LJ; Li Y
Front Immunol; 2020; 11():564099. PubMed ID: 33329526
[TBL] [Abstract][Full Text] [Related]
6. Enhanced cytotoxicity against solid tumors by bispecific antibody-armed CD19 CAR T cells: a proof-of-concept study.
Thakur A; Scholler J; Schalk DL; June CH; Lum LG
J Cancer Res Clin Oncol; 2020 Aug; 146(8):2007-2016. PubMed ID: 32449004
[TBL] [Abstract][Full Text] [Related]
7. Anti-PD-1 antibodies as a salvage therapy for patients with diffuse large B cell lymphoma who progressed/relapsed after CART19/20 therapy.
Wang C; Shi F; Liu Y; Zhang Y; Dong L; Li X; Tong C; Wang Y; Su L; Nie J; Han W
J Hematol Oncol; 2021 Jul; 14(1):106. PubMed ID: 34225766
[TBL] [Abstract][Full Text] [Related]
8. Epigenetic Profiling and Response to CD19 Chimeric Antigen Receptor T-Cell Therapy in B-Cell Malignancies.
Garcia-Prieto CA; Villanueva L; Bueno-Costa A; Davalos V; González-Navarro EA; Juan M; Urbano-Ispizua Á; Delgado J; Ortiz-Maldonado V; Del Bufalo F; Locatelli F; Quintarelli C; Sinibaldi M; Soler M; Castro de Moura M; Ferrer G; Urdinguio RG; Fernandez AF; Fraga MF; Bar D; Meir A; Itzhaki O; Besser MJ; Avigdor A; Jacoby E; Esteller M
J Natl Cancer Inst; 2022 Mar; 114(3):436-445. PubMed ID: 34581788
[TBL] [Abstract][Full Text] [Related]
9. CD19/CD20 Bispecific Chimeric Antigen Receptor (CAR) in Naive/Memory T Cells for the Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma.
Larson SM; Walthers CM; Ji B; Ghafouri SN; Naparstek J; Trent J; Chen JM; Roshandell M; Harris C; Khericha M; Schweppe T; Berent-Maoz B; Gosliner SB; Almaktari A; Ceja MA; Allen-Auerbach MS; Said J; Nawaly K; Mead M; de Vos S; Young PA; Oliai C; Schiller GJ; Timmerman JM; Ribas A; Chen YY
Cancer Discov; 2023 Mar; 13(3):580-597. PubMed ID: 36416874
[TBL] [Abstract][Full Text] [Related]
10. Nonviral RNA chimeric antigen receptor-modified T cells in patients with Hodgkin lymphoma.
Svoboda J; Rheingold SR; Gill SI; Grupp SA; Lacey SF; Kulikovskaya I; Suhoski MM; Melenhorst JJ; Loudon B; Mato AR; Nasta SD; Landsburg DJ; Youngman MR; Levine BL; Porter DL; June CH; Schuster SJ
Blood; 2018 Sep; 132(10):1022-1026. PubMed ID: 29925499
[TBL] [Abstract][Full Text] [Related]
11. Axicabtagene Ciloleucel: Clinical Data for the Use of CAR T-cell Therapy in Relapsed and Refractory Large B-cell Lymphoma.
Halford Z; Anderson MK; Bennett LL
Ann Pharmacother; 2021 Mar; 55(3):390-405. PubMed ID: 32698673
[TBL] [Abstract][Full Text] [Related]
12. Survival Outcomes for Patients with Relapsed/ Refractory Aggressive B Cell Lymphomas Following Receipt of High-Dose Chemotherapy/Autologous Stem Transplantation and/or Chimeric Antigen Receptor-Modified T Cells.
Landsburg DJ; Nasta SD; Svoboda J; Gerson JN; Schuster SJ; Barta SK; Chong EA; Difilippo H; Weber E; Cunningham K; Catania C; Garfall AL; Stadtmauer EA; Frey NV; Porter DL
Transplant Cell Ther; 2023 Aug; 29(8):495-503. PubMed ID: 37211154
[TBL] [Abstract][Full Text] [Related]
13. A cellular antidote to specifically deplete anti-CD19 chimeric antigen receptor-positive cells.
Ruella M; Barrett DM; Shestova O; Perazzelli J; Posey AD; Hong SJ; Kozlowski M; Lacey SF; Melenhorst JJ; June CH; Gill SI
Blood; 2020 Feb; 135(7):505-509. PubMed ID: 31703119
[TBL] [Abstract][Full Text] [Related]
14. Head-to-head comparison of in-house produced CD19 CAR-T cell in ALL and NHL patients.
Itzhaki O; Jacoby E; Nissani A; Levi M; Nagler A; Kubi A; Brezinger K; Brayer H; Zeltzer LA; Rozenbaum M; Vernitsky H; Markel G; Toren A; Avigdor A; Schachter J; Besser MJ
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32152221
[TBL] [Abstract][Full Text] [Related]
15. The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Braendstrup P; Levine BL; Ruella M
Cytotherapy; 2020 Feb; 22(2):57-69. PubMed ID: 32014447
[TBL] [Abstract][Full Text] [Related]
16. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
Levin A; Shah NN
Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
[TBL] [Abstract][Full Text] [Related]
17. Bruton tyrosine kinase inhibitors preserve anti-CD19 chimeric antigen receptor T-cell functionality and reprogram tumor micro-environment in B-cell lymphoma.
Luo W; Li C; Wu J; Tang L; Wang X; Zhang Y; Wu Z; Huang Z; Xu J; Kang Y; Xiong W; Deng J; Hu Y; Mei H
Cytotherapy; 2023 Jul; 25(7):739-749. PubMed ID: 37074239
[TBL] [Abstract][Full Text] [Related]
18. The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
Martínez-Cibrián N; Ortiz-Maldonado V; Español-Rego M; Blázquez A; Cid J; Lozano M; Magnano L; Giné E; Correa JG; Mozas P; Rodríguez-Lobato LG; Rivero A; Montoro-Lorite M; Ayora P; Navarro S; Alserawan L; González-Navarro EA; Castellà M; Sánchez-Castañón M; Cabezón R; Benítez-Ribas D; Setoaín X; Rodríguez S; Brillembourg H; Varea S; Olesti E; Guillén E; Sáez-Peñataro J; de Larrea CF; López-Guillermo A; Pascal M; Urbano-Ispizua Á; Juan M; Delgado J
Br J Haematol; 2024 Feb; 204(2):525-533. PubMed ID: 37905734
[TBL] [Abstract][Full Text] [Related]
19. Risk of HBV Reactivation in Patients With Resolved HBV Infection Receiving Anti-CD19 Chimeric Antigen Receptor T Cell Therapy Without Antiviral Prophylaxis.
Li P; Zhou L; Ye S; Zhang W; Wang J; Tang X; Liu J; Xu Y; Qian W; Liang A
Front Immunol; 2021; 12():638678. PubMed ID: 34335561
[TBL] [Abstract][Full Text] [Related]
20. CD19 occupancy with tafasitamab increases therapeutic index of CART19 cell therapy and diminishes severity of CRS.
Sakemura RL; Manriquez Roman C; Horvei P; Siegler EL; Girsch JH; Sirpilla OL; Stewart CM; Yun K; Can I; Ogbodo EJ; Adada MM; Bezerra ED; Kankeu Fonkoua LA; Hefazi M; Ruff MW; Kimball BL; Mai LK; Huynh TN; Nevala WK; Ilieva K; Augsberger C; Patra-Kneuer M; Schanzer J; Endell J; Heitmüller C; Steidl S; Parikh SA; Ding W; Kay NE; Nowakowski GS; Kenderian SS
Blood; 2024 Jan; 143(3):258-271. PubMed ID: 37879074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
